IFM Investors’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.93M | Buy |
29,661
+2,395
| +9% | +$722K | 0.06% | 283 |
|
|
2026
Q1 | $9.02M | Buy |
27,266
+1,028
| +4% | +$350K | 0.08% | 246 |
|
|
2025
Q4 | $10.4M | Buy |
26,238
+197
| +0.8% | +$87.2K | 0.09% | 205 |
|
|
2025
Q3 | $11.6M | Buy |
26,041
+683
| +3% | +$278K | 0.1% | 179 |
|
|
2025
Q2 | $8.27M | Buy |
25,358
+1,508
| +6% | +$417K | 0.08% | 239 |
|
|
2025
Q1 | $6.44M | Buy |
23,850
+150
| +0.6% | +$38.5K | 0.07% | 265 |
|
|
2024
Q4 | $5.58M | Sell |
23,700
-2,219
| -9% | -$584K | 0.06% | 313 |
|
|
2024
Q3 | $7.13M | Buy |
25,919
+165
| +0.6% | +$43K | 0.07% | 284 |
|
|
2024
Q2 | $6.26M | Buy |
25,754
+103
| +0.4% | +$16.3K | 0.06% | 297 |
|
|
2024
Q1 | $3.83M | Buy |
25,651
+780
| +3% | +$130K | 0.04% | 389 |
|
|
2023
Q4 | $4.76M | Hold |
24,871
| – | – | 0.06% | 314 |
|
|
2023
Q3 | $4.4M | Buy |
24,871
+494
| +2% | +$94.3K | 0.06% | 318 |
|
|
2023
Q2 | $4.63M | Buy |
24,377
+575
| +2% | +$114K | 0.06% | 315 |
|
|
2023
Q1 | $4.77M | Buy |
23,802
+381
| +2% | +$80.1K | 0.07% | 289 |
|
|
2022
Q4 | $5.57M | Buy |
23,421
+3,357
| +17% | +$716K | 0.09% | 242 |
|
|
2022
Q3 | $4.02M | Buy |
20,064
+1,162
| +6% | +$222K | 0.07% | 283 |
|
|
2022
Q2 | $2.76M | Sell |
18,902
-76
| -0.4% | -$10.8K | 0.05% | 370 |
|
|
2022
Q1 | $3.1M | Buy |
18,978
+3,046
| +19% | +$464K | 0.05% | 373 |
|
|
2021
Q4 | $2.7M | Sell |
15,932
-59
| -0.4% | -$11K | 0.05% | 372 |
|
|
2021
Q3 | $3.02M | Buy |
15,991
+75
| +0.5% | +$14.1K | 0.06% | 300 |
|
|
2021
Q2 | $2.7M | Buy |
15,916
+3,503
| +28% | +$513K | 0.06% | 350 |
|
|
2021
Q1 | $1.75M | Buy |
12,413
+1,330
| +12% | +$200K | 0.05% | 402 |
|
|
2020
Q4 | $1.44M | Buy |
11,083
+1,876
| +20% | +$250K | 0.05% | 399 |
|
|
2020
Q3 | $1.34M | Buy |
9,207
+596
| +7% | +$84.7K | 0.06% | 318 |
|
|
2020
Q2 | $1.27M | Sell |
8,611
-2,193
| -20% | -$296K | 0.07% | 297 |
|
|
2020
Q1 | $1.18M | Sell |
10,804
-498
| -4% | -$57.5K | 0.05% | 340 |
|
|
2019
Q4 | $1.3M | Sell |
11,302
-268
| -2% | -$26.7K | 0.05% | 403 |
|
|
2019
Q3 | $930K | Buy |
11,570
+5,747
| +99% | +$455K | 0.03% | 480 |
|
|
2019
Q2 | $423K | Hold |
5,823
| – | – | 0.02% | 552 |
|
|
2019
Q1 | $544K | Buy |
5,823
+660
| +13% | +$55.2K | 0.03% | 475 |
|
|
2018
Q4 | $376K | Buy |
5,163
+367
| +8% | +$28.2K | 0.03% | 510 |
|
|
2018
Q3 | $420K | Buy |
4,796
+657
| +16% | +$66.1K | 0.03% | 501 |
|
|
2018
Q2 | $408K | Buy |
4,139
+1,284
| +45% | +$127K | 0.04% | 481 |
|
|
2018
Q1 | $340K | Buy |
2,855
+202
| +8% | +$26K | 0.05% | 427 |
|
|
2017
Q4 | $337K | Buy |
+2,653
| New | +$333K | 0.05% | 423 |
|
Other funds holding ALNY
IFM Investors's ALNY Position: Q2 2026 in Review
IFM Investors increased its Alnylam Pharmaceuticals (ALNY) stake by 8.8% in Q2 2026, buying an estimated $722K and bringing the position to 29,661 shares worth $8.93M. The position accounts for 0.06% of the portfolio, ranked #283.
IFM Investors first reported a position in ALNY in Q4 2017 and has held it in 35 quarters since. The position peaked at $11.6M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- IFM Investors held 29,661 shares of Alnylam Pharmaceuticals worth $8.93M as of Q2 2026.
- IFM Investors bought 2,395 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $722K.
- Alnylam Pharmaceuticals made up 0.06% of IFM Investors's portfolio in Q2 2026, its #283 holding.
- IFM Investors first reported a position in Alnylam Pharmaceuticals in Q4 2017 and has held it in 35 quarters since.
- IFM Investors's Alnylam Pharmaceuticals position peaked at $11.6M in Q3 2025.
- 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on IFM Investors's 13F filing for Q2 2026, filed 21 Jul 2026.